$14.73
0[0.00%]
At close: Apr 25
$14.73
0[0.00%]
PreMarket: 5:08PM EDT
Arcus Biosciences
(NYSE:RCUS)Arcus Biosciences Stock (NYSE:RCUS), Analyst Ratings, Price Targets, Predictions
Arcus Biosciences Inc has a consensus price target of $45, established from looking at the 38 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Wedbush, and Wedbush on March 25, 2024, February 22, 2024, and January 30, 2024. With an average price target of $36.67 between Truist Securities, Wedbush, and Wedbush, there's an implied 148.93% upside for Arcus Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Wedbush
Mizuho
Morgan Stanley
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Arcus Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/25/2024 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 239.44% | Truist Securities | Robyn Karnauskas | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 103.67% | Wedbush | Robert Driscoll | → $30 | Reiterates | Outperform → Outperform | Get Alert |
| 01/30/2024 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 103.67% | Wedbush | Robert Driscoll | $36 → $30 | Maintains | Outperform | Get Alert |
| 01/30/2024 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 185.13% | Mizuho | Mara Goldstein | $51 → $42 | Maintains | Buy | Get Alert |
| 01/17/2024 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 144.4% | Wedbush | Robert Driscoll | → $36 | Reiterates | Outperform → Outperform | Get Alert |
| 11/13/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 137.61% | Morgan Stanley | Terence Flynn | $38 → $35 | Maintains | Overweight | Get Alert |
| 11/08/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 144.4% | Cantor Fitzgerald | Li Watsek | $46 → $36 | Maintains | Overweight | Get Alert |
| 10/03/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 246.23% | Mizuho | Mara Goldstein | → $51 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 212.29% | Cantor Fitzgerald | Alethia Young | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/07/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 212.29% | Cantor Fitzgerald | Alethia Young | → $46 | Reiterates | Overweight → Overweight | Get Alert |
| 09/06/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 239.44% | Truist Securities | Robyn Karnauskas | → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 56.14% | B of A Securities | Jason Zemansky | $21 → $23 | Maintains | Neutral | Get Alert |
| 08/24/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 198.71% | Citigroup | Yigal Nochomovitz | $41 → $44 | Maintains | Buy | Get Alert |
| 08/23/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 375.22% | BTIG | Kaveri Pohlman | → $70 | Reiterates | Buy → Buy | Get Alert |
| 08/23/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 246.23% | Mizuho | Mara Goldstein | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 157.98% | Morgan Stanley | Terence Flynn | $40 → $38 | Maintains | Overweight | Get Alert |
| 07/12/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 212.29% | Cantor Fitzgerald | Alethia Young | → $46 | Reinstates | Overweight → Overweight | Get Alert |
| 05/26/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 178.34% | Citigroup | Yigal Nochomovitz | $40 → $41 | Maintains | Buy | Get Alert |
| 05/10/2023 | RCUS | Buy Now | Arcus Biosciences | $14.73 | 144.4% | Wedbush | Robert Driscoll | → $36 | Reiterates | → Outperform | Get Alert |
FAQ
What is the target price for Arcus Biosciences (RCUS)?
The latest price target for Arcus Biosciences (NYSE: RCUS) was reported by Truist Securities on March 25, 2024. The analyst firm set a price target for $50.00 expecting RCUS to rise to within 12 months (a possible 239.44% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arcus Biosciences (RCUS)?
The latest analyst rating for Arcus Biosciences (NYSE: RCUS) was provided by Truist Securities, and Arcus Biosciences reiterated their buy rating.
When was the last upgrade for Arcus Biosciences (RCUS)?
There is no last upgrade for Arcus Biosciences.
When was the last downgrade for Arcus Biosciences (RCUS)?
There is no last downgrade for Arcus Biosciences.
When is the next analyst rating going to be posted or updated for Arcus Biosciences (RCUS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arcus Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arcus Biosciences was filed on March 25, 2024 so you should expect the next rating to be made available sometime around March 25, 2025.
Is the Analyst Rating Arcus Biosciences (RCUS) correct?
While ratings are subjective and will change, the latest Arcus Biosciences (RCUS) rating was a reiterated with a price target of $0.00 to $50.00. The current price Arcus Biosciences (RCUS) is trading at is $14.73, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.